Omnipod held its first-ever investor day this week, unveiling a wide slate of updates spanning improvements coming to Omnipod 5 in 2026, a new diabetes insights platform called Discover, details on the next-generation Omnipod 6 system, and an upcoming fully closed loop platform aimed for people with type 2 diabetes. The announcements mark one of the most comprehensive roadmaps Insulet has publicly shared, outlining both software and hardware innovations poised to shape the next several years of its tubeless automated insulin delivery (AID) system.

A major change coming to Omnipod 5’s algorithm includes lowering its base glucose target from 110 mg/dL to 100 mg/dL, a widely requested adjustment aimed at offering tighter glycemic control. The company also highlighted a series of algorithm enhancements meant to improve adaptation, stability, and the amount of time users spend in automated mode. One of the more intriguing updates mentioned was the idea of “extending Podders’ time in automation,” though Insulet did not elaborate on specifics. This could signal efforts to better maintain closed-loop function during exercise, illness, or missed carbohydrate entries, potentially indicating a smarter workout mode or more intuitive pattern recognition.

Insulet also confirmed that by the first half of 2026, Omnipod 5 will be compatible with all major continuous glucose monitors, including Abbott’s Freestyle Libre 3 Plus. Additionally, Omnipod 5 will integrate with Insulet’s new Discover data platform in 2026.

Looking ahead to 2027, Insulet introduced Omnipod 6, the next generation of its AID platform. The pod will keep the same familiar form factor, but it includes major internal and software improvements. These upgrades include stronger Bluetooth connectivity for more reliable connection to CGMs, a universal design that allows a single pod to work across all CGM systems, and a new architecture that lets Insulet deliver future innovations up to six to nine months faster by removing the need for separate manufacturing and stocking for each CGM type.

Omnipod 6 will also feature a fully new adaptive algorithm that learns from each user’s individual insulin needs. The company says the system is especially optimized for users who bolus less frequently and that the new algorithm is designed to deliver more personalized outcomes. Insulet emphasized ease of use and improved wear flexibility as key benefits of this next generation platform.

The device is being developed for both type 1 and type 2 diabetes, which executives say will significantly expand Insulet’s market reach. Leadership also highlighted a redesigned app and controller experience, along with a system foundation built to support rapid software updates and future CGM integrations without delays.

Expected in 2026 is Omnipod Discover, a new insights platform — a powered by machine learning data platform designed to simplify diabetes management for both users and healthcare professionals. The system is already in a limited market release across select clinics in the United States. Discover provides weekly glucose and insulin delivery insights that highlight trends and patterns, helping users better understand and optimize their therapy.

For healthcare providers, the platform offers an intuitive interface that identifies opportunities to improve clinical outcomes and streamlines both onboarding and ongoing management. Discover will support Omnipod 5 and Omnipod DASH, and most likely Omnipod 6, expanding its reach and strengthening Insulet’s move toward more integrated and insight driven diabetes care.

Insulet is preparing a major expansion of its technology with a fully closed loop system designed specifically for people with type 2 diabetes. Planned for release in 2028, the platform is built to operate entirely on its own without meal announcements, carb counting or routine manual adjustments. This level of automation is intended to make advanced insulin delivery far more approachable for people who have never considered using a pump.

A key focus of the system is accessibility. Insulet aims to allow patients to begin therapy through a simple prescription pickup or an in-office sample kit, reducing the complexity that often accompanies diabetes technology. This streamlined experience is expected to support broader adoption among primary care practices and open AID therapy to a much larger portion of the type 2 market, particularly among those who rely on bolus insulin and may later transition to basal-focused use.

The company plans a regulatory submission in 2027 followed by a commercial launch in 2028. Insulet views this platform as an important opportunity to bring automated insulin delivery to millions of people living with type 2 diabetes and to drive its next stage of growth.

While Omnipod currently dominates the patch pump category, competition is heating up. New systems from Medtronic, Tandem Diabetes Care, and Beta Bionics are expected, with some potentially arriving as soon as next year. We’ll be diving deeper into what’s expected for Omnipod 6 in a YouTube video coming out this Friday, along with an All Access article that breaks down every announcement, including those beyond 2028, in much greater detail.

We would love to hear what you think about all these updates. Share your thoughts in the comments below, tell us which feature you are most excited about, and feel free to ask any questions you want us to cover in the upcoming video or article.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.